Alexandria Hammond
Stock Analyst at Wolfe Research
(0.11)
# 4,651
Out of 4,712 analysts
51
Total ratings
48.5%
Success rate
-25%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Alexandria Hammond
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| MRK Merck & Co. | Reiterated: Buy | $135 → $180 | $147.53 | +22.01% | 4 | Aug 25, 2026 | |
| MRNA Moderna | Upgraded: Hold | n/a | $135.61 | - | 7 | Aug 25, 2026 | |
| ABBV AbbVie | Upgraded: Buy | $300 | $250.91 | +19.56% | 3 | Aug 13, 2026 | |
| BIIB Biogen | Upgraded: Buy | $300 | $210.73 | +42.36% | 2 | Aug 13, 2026 | |
| LLY Eli Lilly and Company | Reiterated: Buy | $1,325 → $1,350 | $1,124.21 | +20.08% | 6 | May 21, 2026 | |
| REGN Regeneron Pharmaceuticals | Reiterated: Buy | $1,150 → $860 | $807.65 | +6.48% | 2 | May 18, 2026 | |
| PFE Pfizer | Reiterated: Sell | $25 → $26 | $27.78 | -6.41% | 5 | May 13, 2026 | |
| JNJ Johnson & Johnson | Reiterated: Buy | $200 → $225 | $267.08 | -15.76% | 7 | Oct 15, 2025 | |
| BMRN BioMarin Pharmaceutical | Reiterated: Buy | $95 | $64.41 | n/a | 3 | Jul 15, 2025 | |
| GILD Gilead Sciences | Initiated Coverage: Buy | $110 → $109 | $145.65 | n/a | 3 | Dec 10, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiated Coverage: Hold | n/a | $391.27 | n/a | 2 | Nov 14, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiated Coverage: Hold | n/a | $64.41 | n/a | 2 | Nov 14, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Sell | $150 | $546.66 | n/a | 3 | Aug 7, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $550 | $521.12 | n/a | 2 | Aug 2, 2024 |
Merck & Co.
Aug 25, 2026
Reiterated: Buy
Price Target: $135 → $180
Current: $147.53
Upside: +22.01%
Moderna
Aug 25, 2026
Upgraded: Hold
Price Target: n/a
Current: $135.61
Upside: -
AbbVie
Aug 13, 2026
Upgraded: Buy
Price Target: $300
Current: $250.91
Upside: +19.56%
Biogen
Aug 13, 2026
Upgraded: Buy
Price Target: $300
Current: $210.73
Upside: +42.36%
Eli Lilly and Company
May 21, 2026
Reiterated: Buy
Price Target: $1,325 → $1,350
Current: $1,124.21
Upside: +20.08%
Regeneron Pharmaceuticals
May 18, 2026
Reiterated: Buy
Price Target: $1,150 → $860
Current: $807.65
Upside: +6.48%
Pfizer
May 13, 2026
Reiterated: Sell
Price Target: $25 → $26
Current: $27.78
Upside: -6.41%
Johnson & Johnson
Oct 15, 2025
Reiterated: Buy
Price Target: $200 → $225
Current: $267.08
Upside: -15.76%
BioMarin Pharmaceutical
Jul 15, 2025
Reiterated: Buy
Price Target: $95
Current: $64.41
Upside: n/a
Gilead Sciences
Dec 10, 2024
Initiated Coverage: Buy
Price Target: $110 → $109
Current: $145.65
Upside: n/a
Nov 14, 2024
Initiated Coverage: Hold
Price Target: n/a
Current: $391.27
Upside: n/a
Nov 14, 2024
Initiated Coverage: Hold
Price Target: n/a
Current: $64.41
Upside: n/a
Aug 7, 2024
Reiterated: Sell
Price Target: $150
Current: $546.66
Upside: n/a
Aug 2, 2024
Reiterated: Buy
Price Target: $550
Current: $521.12
Upside: n/a